New Findings in Breast CancerApril 19, 2012
"It is fashionable to think of breast cancer as a disease that can be treated if cancer stem cells are killed off, but we are reporting a sub-population of cancer cells that have no obvious stem cell properties and yet can be tumorigenic and highly aggressive," Bissell says. "The existence of these additional sub-populations of tumorigenic cells tells us that the entire tumor needs to be eradicated, not just one sub-population of basal-like cells."
Bissell is a leading authority on breast cancer and a Distinguished Scientist with Berkeley Lab's Life Sciences Division. Petersen is a professor of Tissue Morphogenesis and Differentiation for CU's Cellular and Molecular Medicine department and a principal investigator for the Danish Stem Cell Center. They are the corresponding authors of a paper in the Proceedings of the National Academy of Sciences that describes this work. The paper is titled "Tumor initiating but differentiated luminal-like breast cancer cells are highly invasive in the absence of basal-like activity." Other co-authors were Jiyoung Kim, René Villadsen, Therese Sørlie, Louise Fogh, Signe Grønlund, Agla Fridriksdottir, Irene Kuhn, Fritz Rank, Vera Timmermans Wielenga, Hiroko Solvang, Paul Edwards, Anne-Lise Børresen-Dale and Lone Rønnov-Jessen.
"Our findings were a surprise to us as we had hypothesized the opposite scenario," Petersen says. "We wanted to learn more about possible tumor suppressive properties so we set out to characterize the bulk of the tumor, which we assumed would not be tumor-initiating."
Most breast cancers originate in the milk ducts and lobules, which consist of luminal cells surrounded by basal cells, and the two most frequent subtypes of human breast cancer cells are named luminal-like and basal-like after their resemblance to the two major lineages in the normal human breast. For the past several years, it has been widely believed that basal-like cells with the undifferentiated qualities of stem cells were the source of invasive tumors. However, since a majority of breast cancers exhibit luminal cell differentiation, the Petersen-Bissell collaboration investigated whether luminal-like differentiated cells within a basal-like cell hierarchy could also become tumorigenic, or must these luminal-like cells acquire basal-like traits to become malignant.
"We applied some rare and mutually exclusive lineage markers to isolate subsets of luminal-like and basal-like breast cancer cells, which enabled us to do single cell cloning with a reasonable success rate," Petersen says. "We enriched for populations with or without prominent basal-like traits from individual tumors, and from single cell cloning of cell lines and recovered cells with a luminal-like phenotype."
What they discovered was that luminal-like cells without specific basal-like traits were fully capable of initiating tumors in laboratory test mice; in fact, the tumors generated by luminal-like cells were larger than those from basal-like cells. In addition, when tested in an invasion assay, these phenotypically pure luminal-like cells were more invasive than the basal-like cells.
"Our findings demonstrate that basal-like cells, as defined currently, are not a requirement for breast tumor aggressiveness and that within a single tumor there are multiple cells with tumorigenic potential," Bissell says. "This casts doubt on the current hypothesis of hierarchical or differentiative loss of tumorigenicity."
The marker used by the Petersen-Bissell collaboration to isolate the luminal-like cancer cells was milk mucin (MM), one of the glycans, the sugar molecules that are ubiquitous to cell surfaces and central to cellular signaling. Basal-like cancer cells were marked with the protein CD271. The MM glycan was detected by the antibody M18. The CD271 marker was detected by the ME20.4 antibody.
In their investigation, the collaborators found that the ability of the luminal-like breast cancer cells to form large invasive tumors depended on the expression of the glycoprotein gene GCNT1, which in turn is required for the MM glycan to be detected by the M18 antibody. The collaborators believe this finding might be of potential clinical importance for breast cancer as co-author Kuhn, a member of Bissell's research group, explains.
"There has been an increasing appreciation that glycans play an important role in malignant behavior and our work shows that inhibiting the activity of GCNT1 could prevent the invasive behavior of the aggressive luminal-like cancer cells if they express the MM epitope," she says.
Although Petersen emphasizes that any clinical implications of this work remains speculative at this time, the finding that multiple types of cells in breast cancers are capable of initiating invasive tumors, he says, could hold implications for future personalized medicine.
"While new avenues in breast cancer targeting have been strongly influenced by the concepts of tumor subtypes and cancer stem cells, we believe our data and recent data from other laboratories opens the possibility of targeting individual stages of differentiation of breast cancer cells within a tumor," Petersen says. "In that way personalized medicine in the future could rely on a cellular-composition-profile with each cellular component accounted for in the treatment design."
This research was supported by grants from the Danish Cancer Society, the Novo Nordisk Foundation, and the Danish Council for Strategic Research, and in part the National Cancer Institute, the breast cancer program of the U.S. Department of Defense, and the U.S. Department of Energy's Office of Science
Lawrence Berkeley National Laboratory
Related Breast Cancer Current Events and Breast Cancer News Articles
Study examines national trends in mastectomy for early-stage breast cancer
Higher proportions of women eligible for breast conservation surgery (BCS) are undergoing mastectomy, breast reconstruction and bilateral mastectomy (surgical removal of both breasts), with the steepest increases seen in women with lymph node-negative and in situ (contained) disease.
Common blood pressure medication does not increase risk of breast cancer, new study finds
Women who take a common type of medication to control their blood pressure are not at increased risk of developing breast cancer due to the drug.
Power behind 'master' gene for cancer discovered
It's hard to believe, but there are similarities between bean sprouts and human cancer.
Vanderbilt study finds more breast cancer patients opting for mastectomy
Far more breast cancer patients are choosing to undergo mastectomy, including removal of both breasts, instead of choosing breast conservation surgery even when they have early stage disease that is confined to one breast, a Vanderbilt study shows.
New approach for treating ALS
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a neurodegenerative disease that primarily kills motor neurons, leading to paralysis and death 2 to 5 years from diagnosis.
First genetic-based tool to detect circulating cancer cells in blood
Metastasis is bad news for cancer patients. Northwestern University scientists now have demonstrated a simple but powerful tool that can detect live cancer cells in the bloodstream, potentially long before the cells could settle somewhere in the body and form a dangerous tumor.
Advances in electron microscopy reveal secrets of HIV and other viruses
UC Davis researchers are getting a new look at the workings of HIV and other viruses thanks to new techniques in electron microscopy developed on campus.
Cutting-edge computer software helps pinpoint aggressiveness of breast cancer tumours
Researchers at Western University are using cutting-edge genetic mutation-analysis software developed in their lab to interpret mutations in tumour genome that may provide insight into determining which breast cancer tumours are more likely spread to other parts of the body and which ones won't.
Molecule fights cancer on 2 fronts
Researchers at the University of Leeds have made a new synthetic anti-cancer molecule that targets two key mechanisms in the spread of malignant tumours through the body.
Researchers describe a mechanism that explains how the breast cancer cells transform normal cells into tumoral ones
Researchers at the Bellvitge Biomedical Research Institute of Bellvitge, the Catalan Institute of Oncology and the University Hospital of Bellvitge have participated in an international study published in the journal Cancer Cell that describes how exosomes secreted by tumor cells contain protein and microRNA molecules capable of transform neighboring cells into tumoral cells promoting tumor growth.
More Breast Cancer Current Events and Breast Cancer News Articles